# Phase 4 Gastrointestinal Tolerability Study of Dimethyl Fumarate in Patients With Relapsing Forms of Multiple Sclerosis in the United States

> **NCT01873417** · PHASE4 · COMPLETED · sponsor: **Biogen** · enrollment: 237 (actual)

## Conditions studied

- Relapsing Forms of Multiple Sclerosis

## Interventions

- **DRUG:** BG00012 (DMF)

## Key facts

- **NCT ID:** NCT01873417
- **Lead sponsor:** Biogen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-05
- **Primary completion:** 2013-11
- **Final completion:** 2013-11
- **Target enrollment:** 237 (ACTUAL)
- **Last updated:** 2017-03-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01873417

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01873417, "Phase 4 Gastrointestinal Tolerability Study of Dimethyl Fumarate in Patients With Relapsing Forms of Multiple Sclerosis in the United States". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01873417. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*